ATE308561T1 - Trail bindender rezeptor - Google Patents

Trail bindender rezeptor

Info

Publication number
ATE308561T1
ATE308561T1 AT98908474T AT98908474T ATE308561T1 AT E308561 T1 ATE308561 T1 AT E308561T1 AT 98908474 T AT98908474 T AT 98908474T AT 98908474 T AT98908474 T AT 98908474T AT E308561 T1 ATE308561 T1 AT E308561T1
Authority
AT
Austria
Prior art keywords
trail
expression vectors
dna sequences
binding receptor
trail binding
Prior art date
Application number
AT98908474T
Other languages
English (en)
Inventor
Charles Rauch
Henning Dr Walczak
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27542220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE308561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE308561T1 publication Critical patent/ATE308561T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98908474T 1997-02-13 1998-02-11 Trail bindender rezeptor ATE308561T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79986197A 1997-02-13 1997-02-13
US81525597A 1997-03-12 1997-03-12
US82953697A 1997-03-28 1997-03-28
US86985297A 1997-06-04 1997-06-04
US08/883,036 US6072047A (en) 1997-02-13 1997-06-26 Receptor that binds trail
PCT/US1998/002239 WO1998035986A1 (en) 1997-02-13 1998-02-11 Receptor that binds trail

Publications (1)

Publication Number Publication Date
ATE308561T1 true ATE308561T1 (de) 2005-11-15

Family

ID=27542220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908474T ATE308561T1 (de) 1997-02-13 1998-02-11 Trail bindender rezeptor

Country Status (13)

Country Link
US (3) US6072047A (de)
EP (2) EP1005488B9 (de)
JP (1) JP5031132B2 (de)
AT (1) ATE308561T1 (de)
AU (1) AU735686B2 (de)
CA (1) CA2279838A1 (de)
DE (1) DE69832178T3 (de)
DK (1) DK1005488T4 (de)
ES (1) ES2251767T5 (de)
HK (1) HK1029796A1 (de)
IL (2) IL131030A0 (de)
NZ (1) NZ336929A (de)
WO (1) WO1998035986A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
NZ337795A (en) 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU738688B2 (en) * 1997-09-12 2001-09-27 Apoxis Sa Cysteine rich receptors-train
AU4561199A (en) * 1998-06-12 1999-12-30 Genentech Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
EP1203024A4 (de) * 1999-07-16 2003-02-26 Human Genome Sciences Inc Humane tumornekrosefaktor rezeptoren tr13 und tr14
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
US6521422B1 (en) 1999-08-04 2003-02-18 Amgen Inc. Fhm, a novel member of the TNF ligand supergene family
WO2001012671A1 (en) * 1999-08-12 2001-02-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr16
US20030134788A1 (en) * 1999-08-12 2003-07-17 Baker Kevin P. Human tumor necrosis factor receptor TR16
EP1220934B1 (de) * 1999-09-27 2005-12-21 Genentech, Inc. Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
AU2006201322A1 (en) * 1999-09-27 2006-04-27 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
EP1272647B1 (de) 2000-04-11 2014-11-12 Genentech, Inc. Multivalente antikörper und deren verwendung
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
KR100436089B1 (ko) * 2000-07-06 2004-06-14 설대우 분비성 재조합 트라이머형의 트레일 단백질 생산을 위한 디엔에이 카세트, 테트라사이클린/독시사이클린-유도성아데노-관련 바이러스 벡터, 이 둘의 조합, 및 이들을이용한 유전자 치료
US20040005314A1 (en) * 2001-07-27 2004-01-08 Enrique Escandon Apo-2l receptor agonist and cpt-11 synergism
IL153948A0 (en) 2000-07-27 2003-07-31 Genentech Inc Apo-2l receptor agonist and cpt-11 synergism
EP1339426A4 (de) * 2000-11-08 2004-06-30 Human Genome Sciences Inc Antikörper mit immunspezifischer bindung an trail-rezeptoren
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030139963A1 (en) * 2000-12-08 2003-07-24 Chickering D. Maxwell Decision theoretic approach to targeted solicitation by maximizing expected profit increases
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
CA2447602C (en) * 2001-05-18 2011-11-01 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7064189B2 (en) 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
EP1420803A1 (de) * 2001-08-08 2004-05-26 Board Of Regents, The University Of Texas System Verfahren zur verstärkung der expression aus einem zellspezifischen promotor
EP2348043A1 (de) 2001-10-02 2011-07-27 Genentech, Inc. APO-2-Ligandvarianten und Verwendungen dafür
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
EP2500032A1 (de) 2002-06-24 2012-09-19 Genentech, Inc. APO-2-Liganden-/Trailvarianten und Verwendungen dafür
JP4741464B2 (ja) * 2003-03-26 2011-08-03 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 改良したＦｃ融合タンパク質
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
RU2431676C2 (ru) * 2004-08-06 2011-10-20 Дженентек, Инк. Анализы и способы с применением биомаркеров
EP2292794A3 (de) * 2004-08-06 2011-07-06 Genentech, Inc. DR Antikörper zur pharmazeutischen Verwendung und Verfahren zur Vorhersage der Sensitivität von Zellen gegenüber solchen Antikörpern mittels Biomarkern
BRPI0515615A (pt) * 2004-09-08 2008-07-29 Genentech Inc métodos para tratar células cancerosas e doença imune relacionada
EP1802660A2 (de) * 2004-09-08 2007-07-04 Genentech, Inc. Verfahren zur verwendung von todesrezeptorliganden und cd20-antikörpern
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5562521B2 (ja) * 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
EP1915626B1 (de) 2005-08-16 2011-11-09 Genentech, Inc. Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
ES2388932T3 (es) 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
US20070218504A1 (en) * 2006-03-09 2007-09-20 University Of Pittsburgh Human leptin-derived polypeptides and uses thereof
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
CN102666588A (zh) 2009-11-05 2012-09-12 Uab研究基金会 治疗基底细胞样基因型癌症
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
SI2636736T1 (sl) 2010-10-29 2016-09-30 Daiichi Sankyo Company, Limited Novo anti-dr5 protitelesce
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
MX2013012716A (es) 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
ES2644022T3 (es) 2013-03-14 2017-11-27 Bristol-Myers Squibb Company Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
EA038551B1 (ru) 2015-12-17 2021-09-14 Дзе Джонс Хопкинс Юниверсити Способ лечения или профилактики системного склероза
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
EP3323428A1 (de) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selektive c-flip-hemmer als antikrebsmittel
EP3910331A1 (de) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835305B1 (de) 1995-06-29 2005-11-23 Immunex Corporation Apoptosis induzierendes cytokin
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
NZ337795A (en) * 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
AU7126498A (en) * 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ATE516354T1 (de) * 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
US6417328B2 (en) * 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU738688B2 (en) 1997-09-12 2001-09-27 Apoxis Sa Cysteine rich receptors-train

Also Published As

Publication number Publication date
EP1005488B2 (de) 2011-12-14
DE69832178T2 (de) 2006-07-20
AU6650598A (en) 1998-09-08
ES2251767T3 (es) 2006-05-01
ES2251767T5 (es) 2012-03-07
CA2279838A1 (en) 1998-08-20
JP2002514069A (ja) 2002-05-14
DE69832178T3 (de) 2012-03-29
EP1676857A2 (de) 2006-07-05
ES2251767T9 (es) 2012-10-17
EP1676857A3 (de) 2007-04-04
US6072047A (en) 2000-06-06
EP1005488B9 (de) 2012-04-18
NZ336929A (en) 2000-11-24
JP5031132B2 (ja) 2012-09-19
EP1005488A1 (de) 2000-06-07
EP1005488A4 (de) 2003-03-05
IL131030A0 (en) 2001-01-28
HK1029796A1 (en) 2001-04-12
IL131030A (en) 2011-02-28
DE69832178D1 (de) 2005-12-08
AU735686B2 (en) 2001-07-12
WO1998035986A1 (en) 1998-08-20
DK1005488T4 (da) 2012-01-16
US6569642B1 (en) 2003-05-27
DK1005488T3 (da) 2006-03-06
EP1005488B1 (de) 2005-11-02
US6642358B1 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
ATE308561T1 (de) Trail bindender rezeptor
ATE353906T1 (de) Cd27 ligand
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
WO1998038212A3 (en) Chimeric polypeptides containing chemokine domains
EP0871702A4 (de) Cytokin lerk-7
HK1013847A1 (en) Gdf-1 and uog-1 proteins
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
WO2007019545A3 (en) Tissue protective peptides and uses thereof
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
MXPA00003885A (es) Quimiocinas con modificiaciones de la terminacion amino.
EP0992584A3 (de) Gereinigte Säugetier FLT3 Liganden und deren Agonisten und Antagonisten
DE69841176D1 (en) Rtd receptor
WO2002005843A3 (en) Human rrp sequences and methods of use
ATE177783T1 (de) Ein menschlicher t-zell rezeptor der protein g- gekoppelte rezeptor familie
EP0692532A4 (de) Neuartige polypeptide, ihre dna, rekombinanter vektor der letzter enthält, mit diesem hergestellter rekombinanter virus und seine verwendung
WO1997036919A3 (en) Cytokine designated lerk-8
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
DE69831584T2 (de) Polypeptide mit wasserkanalaktivität und dna sequenzen
EP0893501A3 (de) ATP-bindendes Ferrichrome Transportprotein
AU5990100A (en) ICBP90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer
WO2001042295A3 (en) Clasp-7 transmembrane protein
EP1019500A4 (de) Neue ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
Black et al. Ferrichrome transport ATP-binding protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1005488

Country of ref document: EP